AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01024101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
Study NCT00379236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUFLEXXA™
Description: EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
Study NCT00379236 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
Study NCT03175874 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hip bone sampling
Description: Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
Study NCT02699125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
Study NCT02699125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
Study NCT02929628 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Beijing PINS Programming
Description: Using the programming control the Stimulator to change the parameter
Study NCT02929628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beijing PINS Programming
Description: Using the programming control the Stimulator to change the parameter
Study NCT02376478 — intervention group
Intervention type: DRUG
Intervention: TNF-alpha inhibitors
Description: therapy for at least 6 months
Study NCT00107510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00107510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT02933268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High water intake
Description: High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
Study NCT02933268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad libitum water intake
Description: Water intake guided by thirst
Study NCT03394846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test of Existing MI Products
Description: Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
Study NCT03881020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine Fluoride 38%
Description: In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
Study NCT03881020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional atraumatic restorative treatment
Description: In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
Study NCT02816099 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prise de sang
Study NCT02816099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prise de sang
Study NCT02452983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT02452983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate/Biopsy
Study NCT00151112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning and plexus anesthesia
Description: positioning during plexus anesthesia
Study NCT00151112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positioning and plexus anesthesia
Description: positioning during plexus anesthesia
Study NCT03849183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
Study NCT03849183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
Study NCT02936180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HD-TIV
Study NCT02936180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SD-QIV
Study NCT01152151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postal reminder letters
Description: Postal reminder letters if adherence is not obtained (up to four)
Study NCT01152151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic reminder letters
Description: Electronic reminder letters if adherence is not obtained (up to four)
Study NCT01152151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letters
Description: up to four reminder letters in september - december 2010
Study NCT01696968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments
Study NCT01696968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo a chest x-ray
Study NCT04229459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation
Study NCT04229459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation
Study NCT04229459 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 1.8 Gy/fraction, 5 days a week for a total of 28 days
Study NCT04229459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy
Study NCT04229459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
Study NCT04607590 — intervention group
Intervention type: OTHER
Intervention: Best Practice
Description: Receive usual care
Study NCT04607590 — intervention group
Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01364181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil 50mg qd po
Study NCT01868893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Study NCT01868893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Study NCT02202863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red wine grape pomace flour (WGPF)
Description: Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
Study NCT03929341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CCTA)
Description: Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
Study NCT03929341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Computed Tomography Angiography (CCTA)
Description: Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
Study NCT03929341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Link
Description: Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
Study NCT03929341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Link
Description: Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
Study NCT00654966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urotensine II
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Study NCT00654966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urotensine II
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Study NCT00654966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble epoxide hydrolase
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Study NCT00654966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soluble epoxide hydrolase
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Study NCT03472417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active partial rebreathing device
Study NCT03472417 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dummy partial rebreathing device
Study NCT04607590 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02674906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACD-A
Description: use of ACD-A as anticoagulant after blood salvage during cardiac surgery
Study NCT04607590 — intervention group
Intervention type: PROCEDURE
Intervention: Yoga
Description: Participate in yoga sessions
Study NCT02674906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: use of heparin as anticoagulant after blood salvage during cardiac surgery
Study NCT03361475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SME App
Description: The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~* Express gratitude to family members (sharing)~* Deliver positive messages regularly (mind)~* Record physical and other joyful activities (enjoyment)~* Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)
Study NCT02338193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPA/MET XR
Description: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
Study NCT02338193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPA
Description: 10 mg dapagliflozin QD for 20-24 weeks
Study NCT02338193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MET XR
Description: 1000 mg Metformin XR BID for 20-24 weeks
Study NCT01212588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Mifepristone 600mg (3x200mg tablets) once daily for seven days
Study NCT01212588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets once daily for seven days
Study NCT03947320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation FVIII
Description: Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Study NCT03003390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given \<24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
Study NCT02737098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Implementation Strategy
Description: The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
Study NCT02737098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation Strategy
Description: Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
Study NCT02140372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1.2 mg followed by 0.6 mg one hour later
Study NCT00656383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clients randomized to nurse-led clinic
Description: Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
Study NCT00656383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clients receive leg ulcer care in their homes
Description: Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
Study NCT00756756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
Study NCT00756756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion of normal saline
Description: 2 week post MI and PCI normal saline was infused
Study NCT02376478 — intervention group
Intervention type: DRUG
Intervention: Alternative/no medication
Description: therapy for at least 6 months or no therapy
Study NCT02376478 — intervention group
Intervention type: OTHER
Intervention: Alternative/no medication
Description: phototherapy for at least 6 months
Study NCT02376478 — intervention group
Intervention type: DRUG
Intervention: Purine/folic acid analogues
Description: therapy for at least 6 months
Study NCT03010904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study NCT03627000 — intervention group
Intervention type: OTHER
Intervention: failure after reimplantation
Description: description of cinical and microbiological failure
Study NCT03628495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression
Description: compression will be delivered using compression garment
Study NCT03628495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression
Description: compression will be delivered using compression garment
Study NCT03628495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusion
Description: occlusion will be delivered using silicone gel sheeting
Study NCT02680119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg DR Capsules of AstraZeneca LP, USA.
Description: oral, crossover
Study NCT02680119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Esomeprazole Magnesium DR Capsules 40 mg
Description: oral, crossover
Study NCT02877316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MYPLAN-safety plan as an application for smart phones
Description: MYPLAN app as a integral part of the standard treatment
Study NCT02877316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: safety plan on paper
Description: Standard treatment with safety plan on paper
Study NCT00410904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Study NCT00410904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT01624610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
Study NCT03260283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pethidine hydrochloride
Description: In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
Study NCT03260283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine HCl Inj 7.5 MG/ML
Description: In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
Study NCT03260283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
Study NCT01154738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine
Study NCT01154738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00
Study NCT00759083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
Study NCT03960658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine-enhanced prolonged exposure
Description: Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
Study NCT02175303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual stromal cell therapy
Description: Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.
Study NCT02667392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait Training with Biofeedback
Description: Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded.
Study NCT02667392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gait Training with Verbal Feedback
Description: Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation.